NewEdge Advisors’s Kyntra Bio KYNB Stock Holding History

NewEdge Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12	Closed	-$810	–	3531
2023 Q2	$810	Buy	+12	New	+$4.96K	﹤0.01%	3277

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's KYNB Position: Q3 2023 in Review

NewEdge Advisors sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 12 shares — an estimated $810 sold.

NewEdge Advisors first reported a position in KYNB in Q2 2023 and held it in 1 quarter. The position peaked at $810 in Q2 2023. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

NewEdge Advisors reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
NewEdge Advisors sold 12 Kyntra Bio shares in Q3 2023, an estimated $810.
NewEdge Advisors first reported a position in Kyntra Bio in Q2 2023 and held it in 1 quarter.
NewEdge Advisors's Kyntra Bio position peaked at $810 in Q2 2023.
110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.